A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma

Cancer

Volumn 120, Issue 23, 2014, Pages 3635-3641

  Skinner, Heath D ^a   Lee, Jeffrey H ^a   Bhutani, Manoop S ^a   Weston, Brian ^a   Hofstetter, Wayne ^a   Komaki, Ritsuko ^a   Shiozaki, Hironori ^a   Wadhwa, Roopma ^a   Sudo, Kazuki ^a   Elimova, Elena ^a   Song, Shumei ^a   Ye, Yuanqing ^a   Huang, Maosheng ^a   Ajani, Jaffer ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Esophageal cancer; MiRNA; Radiation; Response

Indexed keywords

CISPLATIN; FLUOROURACIL; MICRORNA; MICRORNA 145; MICRORNA 451; MICRORNA 505; MICRORNA 99B; OXALIPLATIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY KIT; PATIENT IDENTIFICATION; PREDICTION; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR BIOPSY; ADENOCARCINOMA; ADJUVANT THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CHEMORADIOTHERAPY; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NEOADJUVANT THERAPY; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84913616268     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28911     Document Type: Article

References (27)

1. Jemal A, Bray F, Center M.M., Ferlay J., Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-2084.
3. Herskovic A, Russell W, Liptay M., Fidler MJ, Al-Sarraf M. Esopha-geal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012; 23:1095-1103.
4. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multi-centre, phase 2/3 randomised trial. Lancet Oncol. 2013; 14:627-637.
5. Swisher SG, Winter KA, Komaki R.U., et al. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012; 82: 1967-1972.
6. Sarkaria IS, Rizk NP, Bains M.S., et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients under-going chemoradiation therapy for esophageal cancer. Ann Surg. 2009; 249:764-767.
7. Vallbohmer D, Holscher AH, Dietlein M, et al. [18F] fluorodeoxyglucose-positron emission tomography for the assessment of histologic response and prognosis after completion of neo-adjuvant chemoradiation in esophageal cancer. Ann Surg. 2009; 250:888-894.
8. Erasmus JJ, Munden RF, Truong M.T., et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006; 1:478-486.
9. Ajani JA, Wang X, Hayashi Y., et al. Validated biomarker signatures that predict pathologic response to preoperative chemoradiation therapy (CTRT) with high specificity and desirable sensitivity levels in patients with esophageal cancer (EC). J Clin Oncol. 2011; 29(15 Suppl).
10. Song S, Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2013; 10:109-118.
11. Mayne GC, Hussey DJ, Watson DI. MicroRNAs and esophageal cancer-implications for pathogenesis and therapy. Curr Pharm Des. 2013; 19:1211-1226.
12. Hong L, Han Y, Lu Q., et al. Drug resistance-related microRNAs in esophageal cancer. Expert Opin Biol Ther. 2012; 12:1487-1494.
13. Ko MA, Zehong G, Virtanen C., et al. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiother-apy. Ann Thorac Surg. 2012; 94:1094-1103.
14. Feber A, Xi L, Pennathur A., et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg. 2011; 91:1523-1530.
15. Wu X, Ajani JA, Gu J, et al. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res. 2013; 6:196-205.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.
17. Liu H, Zhu L, Liu B., et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012; 316:196-203.
18. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of pre-operative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009; 27:851-856.
19. Zang W, Wang Y, Du Y., et al. Differential expression profiling of microRNAs and their potential involvement in esophageal squamous cell carcinoma. Tumour Biol. 2014; 35:3295-3304.
20. Nouraee N, Van Roosbroeck K, Vasei M, et al. Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma. PLoS One. 2013; 8:e73009.
21. Fu HL, Wu DP, Wang X.F., et al. Altered miRNA expression is associated with differentiation, invasion, and metastasis of esophageal squamous cell carcinoma (ESCC) in patients from Huaian, China. Cell Biochem Biophys. 2013; 67:657-668.
22. Chu Y, Zhu H, Lv L., Zhou Y, Huo J. MiRNA s in oesophageal squamous cancer. NethJMed. 2013; 71:69-75.
23. Mathe EA, Nguyen GH, Bowman E.D., et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009; 15:6192-6200.
24. Zhao Y, Schetter AJ, Yang G.B., et al. microRNA and inflammatory gene expression as prognostic marker for overall survival in esopha-geal squamous cell carcinoma. Int J Cancer. 2013; 132:2901-2909.
25. Hummel R, Hussey DJ, Michael M.Z., et al. MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. Ann Surg Oncol. 2011; 18:253-260.
26. Hong L, Han Y, Zhang H., et al. The prognostic and chemothera-peutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg. 2010; 251:1056-1063.
27. Guo Y, Chen Z, Zhang L., et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008; 68:26-33.